Radosław Kempiński

Assistant professor

Medical University of Silesia

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Radosław Kempiński is an Assistant Professor at Wrocław Medical University in Poland. His research areas focus on inflammatory bowel diseases, including ulcerative colitis, and the efficacy of various monoclonal antibodies in treatment. He has contributed to numerous studies examining the clinical outcomes and methodologies related to bowel disorders, utilizing both traditional and innovative imaging techniques.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Elżbieta Poniewierka

prof. dr hab.

Uniwersytet Medyczny im Piastów Śląskich we Wrocławiu

POLAND

View details

Malgorzata Krzystek-Korpacka

Wroclaw Medical University

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Radosław Kempiński

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Mirikizumab demonstrates rapid improvements in bowel urgency severity, bowel urgency frequency, and stool deferral time in patients with moderately-to-severely active Ulcerative Colitis: 12-week interim results from the phase 3b LUCENT-URGE trial

Effects of Milk and Dairy on the Risk and Course of Inflammatory Bowel Disease versus Patients’ Dietary Beliefs and Practices: A Systematic Review

EUS in children with eosinophilic oesophagitis – a new method of measuring oesophageal total wall thickness area. An artificial intelligence application feasibility study. A pilot study

Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Inflammatory bowel disease induced by bimekizumab

Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis

Cumulative effective dose from medical imaging in inflammatory bowel disease

Standard versus Endocuff versus cap-assisted colonoscopy for adenoma detection: a randomised controlled clinical trial

Ultrasound elastography in the assessment of the intestinal changes in inflammatory bowel disease - systematic review

The Prevalence of Enteropathy Symptoms from the Lower Gastrointestinal Tract and the Evaluation of Anorectal Function in Diabetes Mellitus Patients

A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Fr531 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Collaborators (2)

Elżbieta Poniewierka

Malgorzata Krzystek-Korpacka

Make your next move.